Scott Gottlieb Quizzed On Big Pharma Ties In FDA Confirmation Hearing
Graphic by Angelie Zaslavsky
President Trump’s nominee to lead the U.S. Food and Drug Administration, Dr. Scott Gottlieb, was questioned about his ties to the pharmaceutical industry by Democrats on a key Senate committee on Wednesday ahead of a vote on whether to advance his nomination for a vote by the full Senate.
Gottlieb, 44, is a former FDA deputy commissioner who has advocated a loosening of requirements needed for approval of new medical products. He is also a resident fellow at the conservative American Enterprise Institute think tank, a partner at a large venture capital fund and sits on the boards of multiple healthcare companies.
Democrats on the Senate Committee on Health, Education, Labor and Pensions, questioned whether Gottlieb’s ties to the pharmaceutical industry would compromise his ability to act impartially.
Senator Chris Murphy of Connecticut said Democrats had “a level of discomfort” with Gottlieb’s nomination, not just due to his private industry background but because of his prior activity as a political advisor to Republican presidential candidates and opposition to the Affordable Care Act.
Overall, the hearing went smoothly for Gottlieb and covered his views on clinical trials, e-cigarettes, the lipoid epidemic and vaccines.
I’m personally matching all gifts to the Forward, up to $36,000. Can I match your gift now?
Hello, fellow Forward reader! I’m Joel Brown, a Forward reader and supporter for more than 15 years, and currently the chair of the board of directors.
I’m an avid Forward reader because it ticks so many of my essential boxes: excellent journalism, Jewish focus and diverse viewpoints. In today’s political climate, what I most appreciate is the Forward’s independence — made possible by the generosity of its membership.
The Forward is committed to bringing you unbiased, nuanced Jewish news. From my position as board chair, I see an exciting future as we expand our position as the definitive independent voice of contemporary American Judaism.
That’s why I’m paying it Forward, by matching $36,000 of reader gifts. It’s an investment in the Forward’s newsroom, to continue telling the American Jewish story with truth and independence.
— Joel Brown, Forward board chair
Support our mission to tell the Jewish story fully and fairly.
